NCT06208748View on ClinicalTrials.gov

SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Gastrointestinal Stromal TumorsGIST
Interventions
DRUG

Bezuclastinib in combination with sunitinib

Bezuclastinib in combination with sunitinib (sutent)

Trial Locations (4)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

33136

RECRUITING

Sylvester Comprehensive Cancer Center, University of Miami, Miami

97239

RECRUITING

Oregon Health & Science University, Portland

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Cogent Biosciences, Inc.
All Listed Sponsors
collaborator

Cogent Biosciences, Inc.

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

The Life Raft Group

UNKNOWN

lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT06208748 - SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST | Biotech Hunter | Biotech Hunter